Additionally, NRs demonstrate excellent anti-tumor efficacy in the ES-2 (p53 S241F) ovarian cancer model and the human tumor xenograft PDX (p53 P72R+/+, C141Y+/+, and L350P+/−) ovarian cancer model, further underscoring their potential clinical application value. Here, TP53 is linked to ovarian cancer.